Posted by Michael Wonder on 24 Jul 2025
Solid Biosciences receives FDA fast track designation for SGT-501 first in class gene therapy for catecholaminergic polymorphic ventricular tachycardia
23 July 2025 - SGT-501 has now received FDA fast track, orphan drug and rare paediatric disease designations.
Solid Biosciences today announced that it received fast track designation from the US FDA for SGT-501, the Company’s novel, AAV-based investigational gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia,
